The effectiveness of α1-blockers on uroflowmetry results in patients with Benign Prostatic Hyperplasia (BPH)

This is the authors' abstract. We don't add key points for this paper.

Background: The incidence of benign prostatic hyperplasia (BPH) increases in patients aged over 50 years. Currently, α1-blocker drugs are routinely prescribed to patients with BPH. One of the evaluations that is often used to assess the success of a patient's treatment with medication is a uroflowmetry examination. This study aimed to assess the effectiveness of administering α1-blockers on uroflowmetry results, specifically Q-max, voided volume, and post-void residual volume (PVR). Methods: This prospective observational cohort study involves patients with BPH who received α1-blocker therapy at one hospital. The uroflowmetry data analyzed includes the Q-max value, voided volume, and PVR, measured before and after one, two, and three months of treatment. The data were analyzed using SPSS version 21.0. Results: From the results, it was found that there was a significant improvement in Q max, voided volume (VV), and post-void residual volume (PVR) before treatment compared to 1 month after treatment and 3 months after treatment, specifically Qmax 8.86±1.87 ml/sec vs. 11.14±1.97 ml/sec vs. 14.02±1.75 ml/sec (p < 0.05), voided volume 142.45±20.42ml vs. 175.51±32.54 ml vs. 204.33±15.88 ml/sec (p < 0.05), PVR 60.95±13.63 ml vs. 50.92±12.32ml vs. 33.76±14.99 ml (p < 0.05). Conclusion: Administering α1-blocker drugs to patients with benign prostatic hyperplasia significantly improves Q-max, voided volume, and PVR within one month of treatment, with maximum results observed after three months.